Brooks Laboratories Limited share price
NSE: BROOKS · ISIN INE650L01011
Key numbers
- Market cap
- ₹ 174 Cr
- Current price
- ₹ 59.01
- 52-week high / low
- ₹ 142 / 36
- Stock P/E
- 13.1
- Book value
- ₹ 41.6
- Dividend yield
- 0.00%
- ROCE
- 21.4%
- ROE
- 22.3%
- Debt to equity
- 0.07
- Sales growth (3 yrs)
- 11.0%
- Profit growth (3 yrs)
- -
- 1-year return
- -59.6%
About Brooks Laboratories Limited
Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries; and trading in pharmaceutical products, ingredients, and intermediaries. In addition, the company offers oncology products and hormonal injections; and formulations for therapeutic areas comprising antibiotic, pain management, controlled drugs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan, Nigeria, Lebanon, Mauritius, Sudan, Madagascar, the Democratic Republic of Congo, Angola, Mozambique, Latin America, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 26 | 23 | 17 | 20 | 23 |
| Operating profit | 3 | 3 | 1 | 1 | 2 |
| Net profit | 10 | 8 | 6 | 2 | -2 |
| EPS (₹) | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 |
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.